Best Biologics / mAb CDMOs in Germany
· updated as new inspection, certificate, and trial data enters the platform
11
CDMOs tracked
6
Fully scored
3
With FDA records
11
FDA inspections
24
EMA/MHRA GMP certs
2
Warning letters
Biologics CDMOs manufacture monoclonal antibodies, fusion proteins, and other large molecules in mammalian (typically CHO) cell culture. It is the largest and most mature segment of contract manufacturing, spanning early clinical supply through multi-thousand-litre commercial production.
Selecting a biologics CDMO turns on bioreactor scale and modality fit (mAb, bispecific, fusion protein), titer and cell-line strategy, fill-finish, and — above all — a clean regulatory record at commercial scale. The rankings below score each CDMO on FDA inspection history, EMA/MHRA GMP certification, clinical-program activity, and capacity.
FDA inspection outcomes across these CDMOs: 5 NAI (no action), 6 VAI (voluntary action), 0 OAI (official action). Leading inspection & GMP sites: Germany (16), United States (8), Italy (4), Portugal (4), China (1).
Last updated 2026-08-27. Sourced from FDA, EMA EudraGMDP, MHRA GMDP, and ClinicalTrials.gov.
| # | CDMO | Signal Score | Quality | FDA · GMP | Capacity | Programs |
|---|---|---|---|---|---|---|
| 1 |
MK
Merck KGaA / MilliporeSigma (CDMO)
Darmstadt, DE · St. Louis, MO
|
81.8 | 98.6 | 2 insp · 2 GMP | — | 22 programs |
| 2 |
RB
Richter BioLogics
Hamburg, Germany
|
82.9 | 100.0 | 0 insp · 9 GMP | — | 0 programs |
| 3 |
CD
Corden Pharma
Plankstadt, DE · Caponago, IT · Boulder, CO
|
82.5 | 99.7 | 4 insp · 10 GMP | — | 0 programs |
| 4 |
EF
Eurofins CDMO
Planegg, DE · San Diego, CA
|
81.6 | 100.0 | 5 insp · 0 GMP | — | 0 programs |
| 5 |
PG
ProBioGen
Berlin, DE
|
78.9 | 100.0 | 0 insp · 2 GMP | — | 0 programs |
| 6 |
SI
Simtra BioPharma Solutions
Bloomington, IN · Halle, DE
|
78.1 | 100.0 | 0 insp · 1 GMP | — | 0 programs |
| — |
Coriolis Pharma
Martinsried (Munich), Germany
|
Profiled | — | — | — | 0 programs |
| — |
Vetter Pharma International GmbH
Ravensburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Boehringer Ingelheim BioXcellence
Ingelheim am Rhein, Germany
|
Profiled | — | — | — | 0 programs |
| — |
Fresenius Kabi
Bad Homburg, Germany
|
Profiled | — | — | — | 0 programs |
| — |
medac GmbH (medac CDMO)
Wedel, Germany
|
Profiled | — | — | — | 0 programs |
What to evaluate in a Biologics / mAb CDMO
Scale & bioreactor fit
Match validated bioreactor scale (from a few hundred litres clinical to 2,000L+ commercial) and single-use vs stainless to your dose and indication. Confirm titer expectations for your construct.
Cell line & process development
Ask whether the CDMO offers its own expression platform/cell line or works from yours, and how process development and tech transfer are handled.
Regulatory track record
Biologics programs heading to BLA/MAA need a strong commercial-scale inspection history. Cross-check FDA 483s, warning letters, and EMA/MHRA GMP coverage — all shown above.
Drug substance to drug product
Confirm whether the CDMO covers fill-finish and formulation in-house or coordinates a separate site, which affects timelines and comparability.
What makes the German CDMO cluster distinctive within Europe?
Germany's CDMO base combines three attributes that shape sponsor decisions: (1) strong biologics + advanced-therapy depth — BioNTech's Marburg site is one of the largest single-facility mRNA operations globally, Boehringer Ingelheim BioXcellence operates commercial-scale biologics at Biberach, and Rentschler carries deep mAb + biosimilar experience; (2) engineering discipline — German pharmaceutical manufacturing has a reputation for process rigor that translates into strong FDA and EMA inspection outcomes; (3) proximity to European pharmaceutical R&D centers, which reduces tech-transfer coordination cost. German CDMOs generally hold BfArM + EMA + MHRA + FDA certifications concurrently for global-market-supplying facilities.
Which German CDMOs specialize in advanced-therapy modalities (viral vector, cell therapy, mRNA)?
Germany hosts substantial advanced-therapy CDMO capacity. Cross-reference with modality pages to filter: mRNA CDMOs (BioNTech Manufacturing Services is Germany's largest), AAV CDMOs, lentiviral CDMOs, cell therapy CDMOs, or the viral vector umbrella. The individual CDMO profile pages surface facility-level modality coverage — critical for advanced-therapy programs where the specific German site's containment class and analytics platform matter more than country-level aggregates.
German CDMOs supplying US and Asian markets
German CDMOs with FDA and Asian regulator inspection history qualify to supply global markets; those without cross-jurisdictional inspection posture are typically limited to EU and MHRA scope. Cross-check with the US region ranking and Asia region ranking to identify German-headquartered CDMOs with global footprint. The Signal Score's Quality Compliance pillar captures FDA + EMA + MHRA data directly, so cross-jurisdictional German CDMOs typically rank higher on this pillar than EU-only competitors.
Biologics / mAb CDMOs — Frequently Asked Questions
Who are the top Biologics / mAb CDMOs?
By CDMO Signal's independent Signal Score, the top-ranked Biologics / mAb CDMOs include Merck KGaA / MilliporeSigma (CDMO), Richter BioLogics, Corden Pharma. See the full ranked table above — scored on FDA, clinical, financial, and capacity data.
How many Biologics / mAb CDMOs have FDA inspection records?
CDMO Signal tracks 3 Biologics / mAb CDMOs with FDA inspection records and 24 EMA/MHRA GMP certificates across the group.
What should I look for in a biologics CDMO?
Match bioreactor scale and modality (mAb, bispecific, fusion protein) to your program, confirm cell-line and process-development support, and prioritize a clean FDA and EMA/MHRA record at the scale you'll commercialize at.
What is the difference between a biologics CDMO and a cell or gene therapy CDMO?
Biologics CDMOs make large molecules (antibodies, proteins) in bioreactors at litre-to-thousands-of-litre scale. Cell and gene therapy CDMOs make living cells or viral vectors in much smaller, often per-patient batches under different containment and analytics.
Related modalities